Chiasma Inc’s Obtaining a FDA Approval of MYCAPSSA Capsules


Pearl Cohen advised Chiasma on the set-up and management of its phase III.

The FDA approved Chiasma Inc.’s MYCAPSSA® (octreotide) capsules for oral treatment of acromegaly, utilizing Chiasma’s Transient Permeability Enhancer (TPE®) technology.

Chiasma, Inc. operates as a biopharmaceutical company, and develops pharmaceutical products for the treatment of acromegaly and hormonal disorders.

The Pearl Cohen team was led by Michal Rom (Picture).

Involved fees earner: Michal Rom – Pearl Cohen;

Law Firms: Pearl Cohen;

Clients: Chiasma, Inc;

Author: Michael Patrini.